The drug comes at a time when antibiotic resistance worries are high. Here’s why it matters.
Programs shown to improve patient outcomes, reduce antibiotic resistance, and decrease healthcare costs.
Prescriptions for COPD contribute to antimicrobial resistance.
New pleuromutilin antibiotic IV and oral tablets.
"Test and treat" scheme reducing stress on general practitioners.